Hemab Therapeutics to Participate in Upcoming Investor Conferences
Hemab Therapeutics (Nasdaq: COAG) announced that its management team will participate in two upcoming investor conferences and host investor meetings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hemab Therapeutics (Nasdaq: COAG) announced that its management team will participate in two upcoming investor conferences and host investor meetings.
The Jefferies Global Healthcare Conference fireside chat is November 17, 2026, at 5:00 PM GMT in London. The 9th Annual Evercore Healthcare Conference fireside chat is December 1, 2026, at 3:00 PM ET in Coral Gables, Florida.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will participate in the following upcoming investor conferences and host investor meetings.
2026 Jefferies Global Healthcare Conference
Fireside Chat: Tuesday, November 17, 2026, at 5:00 PM GMT
Location: London, United Kingdom
9th Annual Evercore Healthcare Conference
Fireside Chat: Tuesday, December 1, 2026, at 3:00 PM ET
Location: Coral Gables, FL
A live webcast of the presentation and fireside chat will be available for replay under “Events & Presentations” section in the Investors section of Hemab Therapeutics’ website at hemab.com.
About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.
Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.
Media:
Deerfield
Peg Rusconi
peg.rusconi@deerfieldgroup.com
Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com
